Ebola Therapeutic

About BioFactura

BioFactura is a private, clinical-stage biotech company with a diversified portfolio spanning biosimilars, biodefense, and novel therapeutics. Its core asset is the patented StableFast™ Biomanufacturing Platform, designed to produce biologics faster, with higher yields, and at lower cost. The company generates revenue through government contracts and grants, particularly for biodefense programs, and has recently launched a CDMO division, Capitol Biologics, to expand its service offerings. With a pipeline featuring both internal and partnered programs in various stages of development, BioFactura operates at the intersection of commercial healthcare and government-funded biodefense.

Therapeutic Areas